false213800QPT8YM6NQZPH282025-03-312026-03-29iso4217:GBP213800QPT8YM6NQZPH282024-04-012025-03-30iso4217:GBPxbrli:shares213800QPT8YM6NQZPH282026-03-29213800QPT8YM6NQZPH282025-03-30213800QPT8YM6NQZPH282024-03-31ifrs-full:IssuedCapitalMember213800QPT8YM…
false213800QPT8YM6NQZPH282025-03-312026-03-29iso4217:GBP213800QPT8YM6NQZPH282024-04-012025-03-30iso4217:GBPxbrli:shares213800QPT8YM6NQZPH282026-03-29213800QPT8YM6NQZPH282025-03-30213800QPT8YM6NQZPH282024-03-31ifrs-full:IssuedCapitalMember213800QPT8YM6NQZPH282024-03-31ifrs-full:TreasurySharesMember213800QPT8YM6NQZPH282024-03-31ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstrumentsMember213800QPT8YM6NQZPH282024-03-31ifrs-full:CapitalRedemptionReserveMember213800QPT8YM6NQZPH282024-03-31ifrs-full:MergerReserveMember213800QPT8YM6NQZPH282024-03-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember213800QPT8YM6NQZPH282024-03-31ifrs-full:RetainedEarningsMember213800QPT8YM6NQZPH282024-03-31213800QPT8YM6NQZPH282024-04-012025-03-30ifrs-full:IssuedCapitalMember213800QPT8YM6NQZPH282024-04-012025-03-30ifrs-full:TreasurySharesMember213800QPT8YM6NQZPH282024-04-012025-03-30ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstrumentsMember213800QPT8YM6NQZPH282024-04-012025-03-30ifrs-full:CapitalRedemptionReserveMember213800QPT8YM6NQZPH282024-04-012025-03-30ifrs-full:MergerReserveMember213800QPT8YM6NQZPH282024-04-012025-03-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember213800QPT8YM6NQZPH282024-04-012025-03-30ifrs-full:RetainedEarningsMember213800QPT8YM6NQZPH282025-03-30ifrs-full:IssuedCapitalMember213800QPT8YM6NQZPH282025-03-30ifrs-full:TreasurySharesMember213800QPT8YM6NQZPH282025-03-30ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstrumentsMember213800QPT8YM6NQZPH282025-03-30ifrs-full:CapitalRedemptionReserveMember213800QPT8YM6NQZPH282025-03-30ifrs-full:MergerReserveMember213800QPT8YM6NQZPH282025-03-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember213800QPT8YM6NQZPH282025-03-30ifrs-full:RetainedEarningsMember213800QPT8YM6NQZPH282025-03-312026-03-29ifrs-full:IssuedCapitalMember213800QPT8YM6NQZPH282025-03-312026-03-29ifrs-full:TreasurySharesMember213800QPT8YM6NQZPH282025-03-312026-03-29ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstrumentsMember213800QPT8YM6NQZPH282025-03-312026-03-29ifrs-full:CapitalRedemptionReserveMember213800QPT8YM6NQZPH282025-03-312026-03-29ifrs-full:MergerReserveMember213800QPT8YM6NQZPH282025-03-312026-03-29ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember213800QPT8YM6NQZPH282025-03-312026-03-29ifrs-full:RetainedEarningsMember213800QPT8YM6NQZPH282026-03-29ifrs-full:IssuedCapitalMember213800QPT8YM6NQZPH282026-03-29ifrs-full:TreasurySharesMember213800QPT8YM6NQZPH282026-03-29ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstrumentsMember213800QPT8YM6NQZPH282026-03-29ifrs-full:CapitalRedemptionReserveMember213800QPT8YM6NQZPH282026-03-29ifrs-full:MergerReserveMember213800QPT8YM6NQZPH282026-03-29ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember213800QPT8YM6NQZPH282026-03-29ifrs-full:RetainedEarningsMember12960219bus:Consolidated2025-03-312026-03-2912960219bus:CompanySecretary12025-03-312026-03-29129602192025-03-312026-03-2912960219bus:Consolidated2026-03-2912960219bus:ChiefExecutive2025-03-312026-03-2912960219bus:Director12025-03-312026-03-29129602192026-03-29xbrli:pure129602192024-04-012025-03-3012960219bus:Consolidatedbus:CompanySecretary12025-03-312026-03-2912960219bus:FRS1012025-03-312026-03-2912960219bus:FullAccounts2025-03-312026-03-2912960219bus:Audited2025-03-312026-03-29

25
26
DR. MARTENS PLC
ANNUAL REPORT FOR THE 52 WEEKS ENDED 29 MARCH 2026

The year
of the
pivot
This is the year of pivot as we make
necessary changes to the business to
execute our consumer-first strategy
and deliver long-term sustainable growth drmartensplc.com

Execution
Laser-focused on delivering our strategy
CEO review p.12
Quality
Improving the quality of our revenue through reducing clearance activity
Consumer p.22
Focus
Distinct product families delivering multi-season growth
Product p.24
Discipline
Capital-light expansion enabling growth in new markets
Markets p.26
Agility
A simplified operating model improving accountability and decision making
Organisation p.28
STRATEGIC REPORT
02 At a glance
04 Brewer Street beacon store
06 Investment case
08 Chair’s Statement
10 Market review
12 CEO review
18 Business model
20 Strategy
22 Strategy in action
32 Finance review
40 Key performance indicators
42 Stakeholder engagement and
Section 172 Statement
48 Risk management and
our principal risks
56 Viability assessment
and going concern
58 Sustainability
77 Climate-related financial
disclosures
87 Non-financial and sustainability
information statement
GOVERNANCE
90 Governance at a glance
92 Chair’s introduction to governance
96 Board of Directors
100 Governance Report
104 Our stakeholders
108 Our culture
112 Nomination Committee Report
120 Remuneration Committee Report
123 Remuneration Report
136 Audit and Risk Committee Report
147 Directors’ Report
FINANCIAL STATEMENTS
154 Independent Auditors’ Report
162 Consolidated Statement
of Profit or Loss
163 Consolidated Statement
of Comprehensive Income
164 Consolidated Balance Sheet
165 Consolidated Statement
of Changes in Equity
166 Consolidated Statement
of Cash Flows
167 Notes to the Consolidated
Financial Statements
214 Parent Company Balance Sheet
215 Parent Company Statement
of Changes in Equity
216 Notes to the Parent Company
Financial Statements
ADDITIONAL INFORMATION
224 Five-year financial summary
(unaudited)
226 First half/second half analysis
(unaudited)
227 Glossary and Alternative
Performance Measures (APMs)
230 Shareholder information
IBC Company information
STRATEGIC REPORT
01
DR. MARTENS PLC ANNUAL REPORT 2026

AT A GLANCE
Our story
We are an iconic British footwear brand
with over 66 years of heritage. Originally
chosen by workers for their air-cushioned
comfort and durability, our products were
adopted by musicians and subcultural
pioneers, who took them from the street
to the global stage.
Financial highlights
Pairs (m)
10.2
2025: 10.5m
Revenue (£m)
764.9
Constant currency
2
: £776.3m
2025: £787.6m
Adjusted EBIT
1
(£m)
79.3
Constant currency
2
: £78.7m
2025: £60.7m
Adjusted PBT
1
(£m)
55.0
Constant currency
2
: £54.2m
2025: £34.1m
Reported PBT (£m)
32.7
Constant currency
2
: £29.8m
2025: £8.8m
1. AlternativePerformanceMeasuresasdefinedintheGlossaryonpages227to229.
2. Constant currency applies the prior year exchange rates to current year results to remove the impact of FX. More information is provided on page 227.
02
DR. MARTENS PLC ANNUAL REPORT 2026

Improved
the quality of revenues through
reducing reliance on discounted
pairs in Americas wholesale
Signed
new and expanded distribution
partnerships for Latin America,
UAE and the Philippines
Grew
our product families, which
now account for 9% of pairs,
triple the FY25 contribution
Simplified
our operating model by eliminating the
regional structure and introducing General
Managers to improve consumer centricity
Strategic highlights
73%
growth in pre-loved pairs sold in the USA through
our resale channel ‘ReWair’
Read more p.62
Repair
First official repair station launched in store
in Brewer Street, London
Read more p.63
98%
Over 98% of leather sourced from tanneries certified
Gold by the Leather Working Group
Read more p.67
Sustainability highlights
What we make
We craft iconic footwear and
accessories with an unwavering
commitment to craftsmanship, heritage,
comfort and durability. Our range spans
boots, shoes, sandals, kids, bags,
accessories and small leather goods.
More information can be found on,
p.20 to 31
STRATEGIC REPORT
03
DR. MARTENS PLC ANNUAL REPORT 2026

BREWER STREET BEACON STORE
In November, we opened our first beacon store at 39 Brewer
Street, Soho, London. This represents a significant step in
how we approach physical retail. Not a traditional flagship
or a model for scale, it redefines the store as a culture-led
destination built for immersion, expression and connection.
This beacon store sets a clear point of view on the future
role of physical retail for the brand.
Culture
crafted
COMMUNITY AND EXPERIENCE
Brewer Street is designed as a cultural and community hub, with
year-round programming that activates the space and extends its role
beyond retail. At its centre is the Doctor’s Orders café, echoing the
brand’s historic café of the same name in Covent Garden in the 1990s,
and created in partnership with social enterprises including Dusty
Knuckle Bakery, Luminary Bakery, Nemi Teas and Old Spike Coffee,
offeringfoodanddrinkthatsupportmeaningfulcausesinthecommunity.
Read more p.72
The store hosts a regular schedule of workshops, talks, live
demonstrations, residencies and music moments, each focused
on creativity and connection, strengthening its identity as a place
where culture, craft and community meet.
ThestorealsointroducesourfirstdedicatedCustomisation&Repair
Bar, enabling wearers to personalise or restore their boots with
expert support.
Read more p.63
04
DR. MARTENS PLC ANNUAL REPORT 2026
DR. MARTENS PLC ANNUAL REPORT 2026

“Brewer Street is where our heritage
and future meet. What excites me most
is the potential for new connections with
our wearers and partners. It feels like a
natural evolution of the way Doc’s have
brought people together for generations.”
CARLA MURPHY
CHIEF BRAND OFFICER
ELEVATED PRODUCT AND COLLABORATIONS
Brewer Street over-indexes in our most premium product, particularly
Made in England (MIE) and collaborations. The store spotlights craft,
offeringMIEexclusivessuchasCityPackLondonandotherrefined
heritage silhouettes, alongside limited-edition collaborations.
The space delivers an immersive, heritage-led experience and
showcases a more premium assortment, with a higher proportion
of product priced £200–£300+ compared with the wider estate.
This has resulted in Brewer Street delivering a higher Average
Selling Price (ASP) and is a test ground for premium retail execution.
Its early performance and customer insights are guiding the next
phase of our retail strategy.
Read more about our retail strategy
CEO review p.15
Rooted in our origins, the ‘Collab Shed’ at Brewer Street takes
inspiration from the small workshop where Dr. Klaus Maertens first
hand tested his air-cushioned sole. The in-store space allows us
to showcase bespoke collaborations and creative residencies, with
partners featured already including Second Best and Metallica.
Other elevated collaborations this year include MM6, Marc Jacobs
and Rick Owens, which sit at the top of the price architecture. The
in-store range has been intentionally tightened to around 150 SKUs,
compared with around 250 in a typical store, reinforcing the focus
on elevated product, exclusivity and refined execution.
STRATEGIC REPORT
05
DR. MARTENS PLC ANNUAL REPORT 2026

INVESTMENT CASE
Our unique proposition
Our competitive
strengths are what set
us apart and position
us to succeed in a
rapidly changing world.
“Our business operates in
an attractive market segment
and we have multiple
opportunities ahead.
Our job is to be disciplined
in growing a resilient and
sustainable model which
maximises both value creation
and value capture, to generate
attractive investor returns.”
IJE NWOKORIE
CHIEF EXECUTIVE OFFICER
06
DR. MARTENS PLC ANNUAL REPORT 2026

Iconic global brand
with deep consumer resonance,
strong engagement levels and
broad, democratic appeal across
genders and ages.
More information can be found in the
Consumer spread p.22
Unique products
with a widely recognised and
protected DNA, supported by
a rich archive to inspire innovation.
More information can be found in the
Product spread p.24
Significant growth opportunity
with meaningful global white space
across new and existing markets,
with opportunity for both consumer
retention and recruitment.
More information can be found in the
Markets spread p.26
Strong product gross margin
with margins generated through
well-controlled sourcing, deep supplier
partnerships and a resilient, responsive
supply chain and distribution network.
More information can be found in the
Finance review p.32
Highly cash generative
with low capital requirements
and a resilient Balance Sheet.
More information can be found in the
Finance review p.32
Passionate culture
with a focus on innovation, doing the
right thing and leaving things better than
we found them for the next generation.
More information can be found in the
Organisation spread p.28
1
2
3
4
5
6
STRATEGIC REPORT
07
DR. MARTENS PLC ANNUAL REPORT 2026

CHAIR’S STATEMENT
our
mindset
PAUL MASON
Chair
“FY26 was year one of the new team executing the new strategy and,
whilst there of course remains much work to do, I’m pleased with progress
to date. The business has been reorganised to be consumer-led, as
opposed to channel-led, revenues are higher quality and we have returned
to growing profit. The Board continues to give constructive challenge
to the Executive Team and we look to the year ahead with confidence.”
Shifting
08
DR. MARTENS PLC ANNUAL REPORT 2026

In last year’s Annual Report we shared the new strategy for the
business and laid out the four objectives under this strategy for FY26.
We have delivered against all four: revenue is higher quality, with less
clearance activity; the contribution from product families has grown;
we have signed a number of new distribution agreements; and,
crucially, we have reorganised the operating model to deliver the
newconsumer-firststrategy.Thisreorganisationhasinvolvedmany
colleagues across the business and as is always the case, has been
difficult at times and I would like to extend the Board’s gratitude
for the professionalism and dedication of everyone involved.
As part of this simplification of the operating model Ije has also
introduced an Executive Team structure, with fewer direct reports,
greater accountability and an enterprise-wide approach to
leadership structures. This is an important evolution for the
business and we’re already seeing the benefits of this approach.
You can read about this team on pages 30 and 31.
FY26 revenue was slightly down (2.9% reported, 1.4% CC) in
line with our guidance. Our results, however, show green shoots
of the new strategy: the USA is back into growth with Full Price
DTC revenue up 14%, the performance of our shoes has been
very strong, up 19%, and we have had a year of strong product
collaborations and a great reaction to our first beacon store, in
Brewer Street, London. There remains more work to do and we
are focused on driving overall topline growth.
FurtherdowntheP&Ltheresultsalsospeaktothesignificantamountof
work done by the team on costs, both the cost action plan of FY25 and
a wider cultural reset around good cost control. This, combined with
the continued strong gross margin, is the main driver behind the 61%
Adjusted PBT growth and 75% EPS growth we achieved in the year.
The Balance Sheet remains strong, with net bank debt, if we exclude
leases, of £69.7m, which compares to a peak of net bank debt
of £271.8m at H1 FY24. When leases are included, net debt now
stands at £213.5m, representing 1.4x EBITDA, a comfortable
position. Giles shares how we think about capital allocation in
the Finance review on page 32.
GOVERNANCE
With no changes in Board membership during the year, we were able to
focus fully on supporting and challenging Ije and Giles as they executed
the new strategy, while still affording succession planning due and
proper attention through the work of the Nomination Committee.
The Board’s governance focus in FY26 centred on maintaining
disciplined decision-making through the reorganisation, ensuring
internalcontrolsandfinancialrigourremainedstrong,andsupporting
the leadership team as the new operating model was implemented
and bedded in. We also continued our regular monitoring of
developing governance and reporting requirements, ensuring we had
the clarity and visibility needed as roles and accountabilities evolved.
The operating model changes also provided a natural opportunity for
the Board to reflect on whether our collective skills and experience
remained aligned to the needs of the organisation. With the
observations from last year’s external Board Effectiveness Review
providing a strong foundation, we have continued to reassess
our capabilities to support the next phase of the strategy. This has
fed into the Board’s FY26 internal Effectiveness Review, which
was ongoing at the time this Annual Report was approved. More
information on this and the activities of the Board and our principal
Committees during the year can be found in our Governance Report
from page 88.
PEOPLE
The people of Dr. Martens remain passionate, talented and
dedicated and the Board continues to be impressed and grateful
for this culture. Ije has brought a renewed focus to better equipping
and enabling our people to do their life’s best work. Simplifying
the operating model through the recent reorganisation plays an
important part of this, as does technology, and this topic will remain
one under active Board discussion in the year ahead.
SUSTAINABILITY
We are in the process of evolving our sustainability strategy and you
can read more about this, and our progress against our sustainability
commitments, in our Sustainability Report on page 58 onwards.
What doesn’t change is the timeless design, longevity and durability
of our products and the care and commitment we have to leaving
things better than we found them.
DIVIDEND
The Board is proposing a maintained final dividend of 1.70p,
reflecting our commitment to shareholder returns while aligning
with our long-term payout strategy.
As I did last year, I would like to end this statement with thanks to
our supportive shareholders. We are in the early stages of executing
the new strategy and, whilst I am convinced we are on the right path,
the journey will inevitably have its bumps along the way. We are also
operating in an uncertain trading environment. We remain
committed to transparent communication and are firmly focused
on returning the business to profitable, sustainable growth.
PAUL MASON
CHAIR
19 May 2026
Changing both CEO and CFO, particularly as a publicly listed
company, isn’t without risks and, as shared in last year’s report, the
Board was considered and thoughtful in our approach. Furthermore,
the pairing of and dynamic between these two crucial roles is as
much an art as a science. As we look back on the first year of Ije
and Giles executing the new strategy, I am very pleased with the
leadership they have given the business, the relationship that they
have forged and the strategic heavy lifting they have done.
STRATEGIC REPORT
09
DR. MARTENS PLC ANNUAL REPORT 2026

The environment we operate
in matters. Macroeconomic
and market trends directly
shape how consumers
behave and where risks
emerge for our business.
MARKET REVIEW
Industry
trends
10
DR. MARTENS PLC ANNUAL REPORT 2026

96.5
97.0
97.5
98.0
98.5
99.0
99.5
100.0
100.5
101.0
101.5
202620252024202320222021202020192018
MACROECONOMIC VOLATILITY
The global economy remains fragile, with
monetaryandfiscalpolicyuncertainty,market
volatilityandinflationcontinuingtoweighon
consumerconfidence.Consumptiongrowth
in 2026 is expected to remain subdued,
with significant variation between markets.
How we are responding
- Introduced a General Manager
structure across our six largest
markets, strengthening local
consumer insight and enabling faster,
market-specific decision-making
- Diversifying revenue and profit
across markets, channels and product
categories, making us a more
resilient business
- Maintaining disciplined, consumer-led
investment decisions across products,
channels and markets to support
long-term value creation despite
macro volatility
- Strengthening planning, data and
governance to enable faster in-year
decisions and execution
- Continued focus on productivity and
efficiency,utilisingAIanddataanalytics
to support business performance
CONSUMER ENVIRONMENT
Value-conscious consumers
Cost of living pressures across major
developed markets continue to dampen
sentiment, with consumers spending
more selectively and remaining highly value
conscious. Shoppers continue to seek
discounts, particularly in European markets
where promotional intensity has been
very pronounced during seasonal peaks.
Consumption is increasingly polarised,
with demand concentrated at lower-priced
essentials and premium products, placing
pressure on the mid-market.
Category divergence
Consumers are increasingly favouring
footwear that can be worn across multiple
occasions, prioritising comfort and everyday
functionality. While demand indicators in
the US point to ongoing softness in parts
of the footwear market overall, performance
continues to vary by market and category.
Lifestyle and performance footwear have
proven more resilient than fashion-led
categories, reinforcing the relative strength
of brands with clear functionality and
versatility. In this environment, consumer
expectations around value continue to rise,
increasing the importance of clear reasons
to buy and consistently strong execution
across all touchpoints.
How we are responding
- Building consumer trust through
disciplined, consistent pricing
and a more considered approach
to promotions
- Reinforcing our premium positioning
through product storytelling focused
on craft, quality and durability,
supported by our collaborations
and Made In England (MIE) range
How we are responding
- Expanding everyday relevance beyond
boots to increase purchase occasions,
through disciplined category growth in
shoes and sandals
- Newness discipline, with fewer, more
impactful launches and product families
focused on serving a distinct consumer
need across multiple seasons
+10.5pp
increase in UK consumers
actively chasing discounts
+5.9pp
increase in planned, controlled spending
Source: Deloitte UK Consumer Tracker.
Volatile and uneven demand
Consumer confidence varies by region,
making demand harder to predict. Over the
past year, OECD consumer confidence has
remained below long-term averages, with
stabilisation in the USA and parts of APAC
and Latin America, but continued weakness
across EMEA.
Consumer confidence index (CCI)
Amplitude adjusted, Long-term average = 100
Source:Consumerconfidenceindex.
STRATEGIC REPORT
11
DR. MARTENS PLC ANNUAL REPORT 2026

the
pivot
Year
of
CEO REVIEW
IJE NWOKORIE
Chief Executive Officer
12
DR. MARTENS PLC ANNUAL REPORT 2026

STABILISE
PIVOT
SCALE
FY25 FY26 FY27 FY28
Our Levers for Growth strategy has three phases: stabilise, pivot
and scale. During FY25 we successfully stabilised the business.
FY26 was centred on pivoting the business to being truly consumer-
first. This involved hard calls and a huge amount of heavy lifting to
ensure that we shifted from being channel-led to consumer-first,
pulling back on clearance activity across the business in both DTC
and wholesale to improve the quality of our revenue, putting in
place a world-class leadership team and reorganising our business
to simplify how we operate and drive accountability.
There is more work to do in pivoting the business, however in FY27
we will also enter the scale phase of the strategy. This does not
mean volume at any cost. It means scaling higher-quality revenues
and operational leverage, underpinned by a more resilient model.
The desire for our brand is strengthening and we will leverage
this momentum, increasing brand investment and delivering our
improved retail strategy. The retail strategy is centred on moving
from a transactional one-size-fits-all model to a tiered retail estate
which repositions retail as a growth engine, with investment in
high potential stores. These investments, in both our brand and
our physical estate, will further support growth.
In FY26 we returned the business to
profit growth, delivering a 61% increase
in adjusted PBT, with revenue in line
with guidance, and made good progress
pivoting the business to a consumer-first
operating model. Our focus on execution
is paying off: we are improving the quality
of revenues whilst strengthening margins,
cash generation, the Balance Sheet and
overall model resilience.
“There is still work to do in pivoting the
business, however in FY27 we will also
enter the scale phase of our strategy.
With the operating model reset, key
capabilities in place, combined with
good visibility of our wholesale order
books, our business is now well setup
to deliver both our FY27 objectives
and medium-term targets.”
Our overarching ambition is to establish Dr. Martens as the world’s
most-desired premium footwear brand. Building brand desire is
therefore central to our ambition, and there is clear evidence that
brand desire is strengthening: world-class collaborators continue
to approach us to partner with them, our wholesale relationships are
deepening, consumer response to new product launches is strong
and the impact of our first beacon store in Brewer Street, London,
has exceeded our expectations. Further fuelling brand desire
remains a key focus of the teams in the year ahead.
STRATEGIC REPORT
13
DR. MARTENS PLC ANNUAL REPORT 2026

CEO REVIEW CONTINUED
CONSUMER
Our FY26 consumer objective was to reduce the reliance on
discounted pairs in Americas wholesale. We achieved this objective,
with off-price USA wholesale pairs declining 31%. The quality of
our wholesale order books also continues to improve, with better
diversification across product categories and silhouettes, and
more tailored product assortments by wholesale customer based
on their consumer mix.
Beyond wholesale, we focused on improving Full Price DTC sales
mix across our major markets by reducing the length of clearance
periods and the depth of discount offered. In FY26 we delivered
Full Price DTC revenue up 1%, with Full Price DTC mix improving
3pts. However, this performance masks the strength of our largest
market, the USA, together with key APAC markets. USA Full
Price DTC revenue was up 14% and mix up 9pts, and in our APAC
markets, led by Japan and South Korea, with Full Price DTC
revenue up 15% and mix up 8pts. EMEA was impacted by increased
consumer participation in clearance, resulting in a 4pts decline in
Full Price DTC mix, with Full Price DTC revenue down 13%. With
Full Price mix successfully addressed in USA and APAC markets,
growing Full Price mix in our largest EMEA markets is a priority for
FY27. Our new market structure, with dedicated General Managers
for our largest markets, is a key enabler of this.
Craft Curators are premium consumers with a strong attachment to
product quality and heritage, and our consumer strategy is centred
on growing our share of this consumer group. We have started to
see our actions translate into growing our share of Craft Curators,
with our share now the highest it has been since FY21 when we
started measuring it, and the in-year improvement more than
reversing the declines seen in FY24 and FY25. The growth in Craft
Curators can also be evidenced in the performance of our Lowell
product family, where pairs more than quadrupled year-on-year,
and we expect further significant growth in Lowell in FY27.
Read more about our
Consumers p.22
PRODUCT
The FY26 objective of driving pairs growth in the product families
of Buzz, Zebzag and Lowell was exceeded, with these families now
accounting for 9% of pairs, triple the contribution in FY25 (3% of
pairs). Building multi-season product families that serve specific
consumer needs and broaden our appeal alongside our iconic and
continuity lines is central to driving more purchase occasions.
Shoes and the new product families are the current growth engine.
Shoes continue to perform very strongly, with revenue up 19% in
FY26 across a wide range of silhouettes. This includes new product
families of Buzz and Lowell, together with iconic styles including the
1461 Shoe, the Adrian Tassel Loafer and the Mary Jane. Shoes now
account for 31% of revenue, up from 26% in FY25.
Boots are showing signs of stabilisation, with encouraging Full Price
performance in USA. Boots revenue declined by 8%, however within
this Full Price boots performed better, particularly in USA, where
Full Price DTC boots were in growth in all but the first quarter of
FY26. Encouragingly, the 1460 Boot was in growth in Full Price DTC
in Q4 in USA. Within our boots range we continued to see success
with taller boots, led by the Kasey, and had strong-performing boot
collaborations such as Rick Owens and Metallica. Boots accounted
for 52% of Group revenue in FY26, down from 57% in FY25.
Sandals are a known gap with a fix in progress. Sandals revenue
declined 11%, as anticipated and communicated in our first half
results, given the lack of new products in the SS25 range. We did,
however, see continued good performance from our Zebzag range
across both sandals and mules. SS26 marked an improvement in
our sandals range, again led by the USA, however we don’t expect
to see a significant change in our sandals performance until SS27,
when the redeveloped range launches. Sandals accounted for 11%
of Group revenue in FY26, down from 12% in FY25.
Bags and Accessories are a long-term growth opportunity, with
good early results. Bags revenue grew by 15% with particular
success in the Top Handle Kiev across multiple colourways.
Small Leather Goods, a relatively new area for us, continue to
perform well, particularly in retail stores. Bags and other accounted
for 6% of Group revenue in FY26, up from 5% in FY25.
Across our ranges we have seen consumers continue to buy into
higher price point lines across all categories. Products priced over
£220 are the fastest-growing price category in DTC; whilst still
small as a proportion of the overall business, the price band of £220
and above doubled in FY26. Higher price point products which
performed strongly in FY26 include the Kasey knee-high boot (£210
/ €240 / $250), the Made In England (MIE) Penton Classic Calf
Loafers (£220 / €260 / $260), the Weekender Ambassador Leather
bag (£310 / €330 / $330), and the success of our collaborations
such as Rick Owens 1B60 Pentalace boots (£390 / €420 / $480) and
Dr. Martens x Marc Jacobs Kiki boots (£290 / €320 / $290) (shown
in left image). This movement up the price architecture is supportive
to gross margin and aligned with our strategy.
Read more about our
Products p.24
14
DR. MARTENS PLC ANNUAL REPORT 2026

RETAIL STRATEGY REVIEW
Our store estate today has many strengths but
also has significant opportunity for improvement.
The output of the review is that we are categorising our existing and future store estate across four tiers, with each having clear
financial hurdle rates and criteria including product assortment, location characteristics and brand objectives. The four tiers are:
FOUR TIER MODEL AND DISCIPLINED CAPITAL ALLOCATION
Between FY21 and FY24, in line with the DTC-first strategy, the
store estate expanded significantly, doubling from 122 to 239 stores.
In contrast, FY24 retail revenue was only up by c.50% compared to
pre-Covid FY20 levels. The financial performance was compounded
by an undifferentiated retail format that meant even stores in good
locations did not present a retail experience fit for that market.
During FY26 we carried out a comprehensive review of our retail
estate and strategy. This included detailed financial analysis,
location assessment and an evaluation of the strategic value
of each store, specifically around building brand desire, growing
consumer engagement and driving purchase occasions.
In November, we opened our first beacon store, in Brewer Street,
London. This store was centred on premium and craft curators
and has been designed with community events and activations
in mind. ASP is over 15% higher than other London stores and
the contribution from both MIE and products over £220 much
higher than the average. These proof points give us confidence
and important learnings to build upon in the years ahead.
Read more on
p.04
In March we opened Dosan Park, Seoul, a brand centre store.
This space showcases our MIE icons, exclusive product and a
dedicated Craft Zone where visitors can experience Dr. Martens
craftsmanship firsthand. The store was developed utilising
successful elements from Brewer Street, such as MIE and Bags
&Accessoriesareas,andearlyresponsehasbeenencouraging.
BEACON STORE
An immersive brand
destination where
consumers experience the
full expression of heritage,
culture and creativity.
1
BRAND CENTRE
A destination to explore
the full brand, offering depth,
expertise and elevated
experience.
BRAND STORE
Offering a clear, convenient
and engaging store that
makes it easy to shop the
best of the brand.
OUTLET
An accessible entry to the
brand,offeringvaluewithout
compromising identity.
2 3 4
Invest in around 30 high potential stores, focused
predominantly on elevating them into brand centres.
These will take the learnings from the success of Brewer
Street and Dosan Park. The investment is included within
our capex guidance.
Experiment and launch further retail concepts in key
cities globally.
We anticipate that the overall store estate will be largely unchanged in size over the coming few years.
BREWER STREET BEACON STORE AND DOSAN PARK BRAND CENTRE: PROOF OF CONCEPT
The majority of our store estate today are Brand stores. Over the next 12-24 months, we will:
STRATEGIC REPORT
15
DR. MARTENS PLC ANNUAL REPORT 2026

Ije Nwokorie and
Giles Wilson sit down
to discuss a defining
year for Dr. Martens
Q&A
Last year, you spoke about the need to
stabilise the business. This year has
been described as the year of the pivot.
What specifically changed in how
Dr. Martens operates?
GILES: Last year we stabilised the business,
reducing our cost base, strengthening the
Balance Sheet and right-sizing inventory
across both our business and our wholesale
customers. All this work meant that we
had a stable base going into FY26 to begin
executing and implementing our new
consumer-first strategy.
IJE: Arguably the biggest change we’ve
made this year was to how our business is
structured and organised – we refer to this
as our operating model. We’ve taken out
our regional layer and instead strengthened
our Group functions, particularly our brand
organisation, and introduced General
Managers for all of our key markets: UK,
DACH, France, Italy, Japan and USA.
This means we can truly put the consumer
at the heart of our decisions, as opposed
to having a regional and channel approach
wherebydifferentchannelswereessentially
competing with each other.
GILES: We’ve also focused on improving
the quality of our revenues by growing Full
Price mix, signed a number of distribution
agreements to unlock growth in new
markets, and opened our first beacon
store in Brewer Street, London, which we’re
learning a lot from. You can read about
these in more detail on pages 4, 22 and 26.
A key focus this year has been improving
the quality of revenues and earnings
rather than chasing volume. How has
that shown up in financial performance?
GILES: We returned to a more disciplined
approach to promotions across our business,
and saw particular success in USA and
our APAC markets. Full Price DTC revenue
was up 14% in Americas and 15% in APAC.
CEO REVIEW CONTINUED
MARKETS
Our FY26 markets objective was to open in new markets through a
capital-light structure.
We over delivered against this objective, with the momentum and interest
from world-class partners meaning we signed new and expanded distribution
partnerships for Latin America, UAE and the Philippines.
Across all our major markets we have been working more closely with wholesale
accounts to launch new products and to put the consumer at the heart of our
collective decision making and activity. Examples include: working with our
largest EMEA wholesale partners on our Buzz, Lowell and Zebzag product
launches; working with our largest USA wholesale partners across both our
new product families and iconic products such as the Adrian tassel loafer; and
working with our key partners in South Korea on our 1461 shoe. We have also
worked with pinnacle wholesale partners as they showcase our products, such
as the Rejena boot and Delapre Penny Loafer, to their consumers. An important
part of deepening wholesale relationships is working with our partners to
curate their product assortments in line with their consumer base, resulting
in differentiated order books across our wholesale customer base; again
we are making significant strides in this area.
Read more about our
Markets p.26
ORGANISATION
Our FY26 organisation objective was to simplify the operating model to
operate closer to individual markets. This was achieved with the reorganisation
of the business. We are also making significant strides using technology to
drive productivity.
We have simplified the leadership structure with the creation of an eight-person
Executive Team, which sets business direction and has an enterprise-level view.
This compares to the previous 12-person Global Leadership Team, which had
a combination of functional and regional responsibilities. Under the Executive
Team is now a clearly defined Leadership Team, consisting of market and
functional-level leaders.
In Q4 we restructured the business, removing the regional structure and
introducing General Managers (GMs) for all our largest markets. Alongside this,
we have invested in our central brand and product organisation, strengthening
particularly the marketing, merchandising and the customer experience functions,
bringing greater focus to the end-to-end consumer experience and journey.
Technology is fuelling productivity, with AI being thoughtfully deployed across
the business. The establishment of a Global Technology Centre (GTC) in
India, first created in FY25 and expanded and embedded in FY26, is delivering
material benefits. The GTC brought core engineering in-house to better enable
us to leverage the opportunities of data and AI and to significantly speed up
technology delivery. Key systems are now fully live and delivering benefits
to the business, with more to come in the years ahead.
Read more about our
Organisation p.28
IJE NWOKORIE
CHIEF EXECUTIVE OFFICER
19 MAY 2026
16
DR. MARTENS PLC ANNUAL REPORT 2026

We have more work to do in our EMEA
markets, where Full Price DTC revenue
was down 13%, and this will be an area of
focus for FY27. The overall improvement in
Full Price mix supported our gross margin
and was also a driver of the 270bps
improvement in Adjusted EBIT margin.
IJE: We’re also focused on growing
customer lifetime value, and being able
to really target why different consumers
are buying from us. That’s something
we’re really focused on and our customer
data platform gives us the tools to improve
this further in the years ahead.
What is the core shift in Dr. Martens’
strategy, and how does it reposition the
brand for sustainable, long-term growth?
IJE: Ultimately, the key criteria for success
of the new strategy will be that no single
market, channel or category represents
an outsized risk for the business.
GILES: In the past the business was
too reliant on certain styles of boots,
andspecificmarketsandchannels,and
whengrowthstalled,therewassignificant
operationaldeleveragethroughtheP&L,
with the revenue decline having a big impact
on profitability.
IJE: The new strategy is about taking a
market by market approach to channels,
broadening our consumer appeal and giving
consumers more reasons to buy across
our product range.
More information can be found in the
Strategy in action section p.22
With the pivot now underway and
early progress visible, what gives you
confidence in the next phase – and where
do you remain deliberately cautious?
IJE: We’re really pleased with the green
shootswe’veseeninthefirstyearofthenew
strategy. The foundations of our business
are really strong – we have a world-class
supply chain, modern technology systems
architecture, a clear product strategy and
great talent across the business.
GILES: We’re clearly operating in uncertain
macroeconomic times, and so, whilst
we’re focused on executing our strategy
and controlling what we can control, there
are external factors which may impact
our business.
IJE: What we’re really prioritising day
to day is execution, ensuring that people
are able to do great work and we’re set
up in a way which creates the best value
for our stakeholders.
Your sustainability strategy is evolving,
are you still as committed to sustainability
as previously?
IJE: Absolutely, our commitment to
sustainability is unchanged, but our
approach is evolving to place the consumer
at the centre of every decision. While
continuing to meet our existing responsibility
commitments,wearerefocusingourefforts
on embedding circularity services like repair
and resale into the consumer journey,
ensuring they are consistent and engaging.
Read more about how we’re evolving
our sustainability strategy p.58
STRATEGIC REPORT
17
DR. MARTENS PLC ANNUAL REPORT 2026

V
a
l
u
e
c
a
p
t
u
r
e
V
a
l
u
e
c
r
e
a
t
i
o
n
DEFINING OUR BUSINESS
Dedicated colleagues
We employ people who go the extra
mile. They have dedication and passion
for our brand and consumers.
Sustainabilityembedded
Sustainability includes circularity, ethical
supply chains, responsibly sourced
materials, and social responsibility
programmes, ensuring environmentally
conscious, durable products and operations.
Modern systems architecture
Our technology platform means we
can operate at scale, and supports
data-driven, AI-enabled decision-making.
World-class supply chain
We maintain supply chain resilience
through diversified manufacturing,
strong supplier relationships, long-term
sourcing, agile logistics and global
operational flexibility.
Iconic brand heritage and IP
We leverage decades of cultural
relevance and strong IP to maintain
authenticity, premium positioning
and an enduring competitive advantage.
Consumer brand loyalty
Long-term relationships are built with
wearers as a brand, not just footwear.
Our consumers act as ambassadors
with a deep cultural connection and
loyalty, fostering advocacy.
MARKETING
Broaden the
consumer base
through craft
MARKETPLACE
Create premium buying
and ownership
experiences
across channels
and markets
BUSINESS MODEL
An iconic
brand
P
R
E
M
I
U
M
G
L
O
B
A
L
B
R
A
N
D
M
A
R
K
E
T
A
N
D
C
U
S
T
O
M
E
R
I
N
S
I
G
H
T
S
Consumer
first
“EARN THE
RIGHT WITH
EACH WEARER”
PRODUCT
Iconic products
across footwear
and bags
RESOURCES AND RELATIONSHIPS
18
DR. MARTENS PLC ANNUAL REPORT 2026

GLOBAL REVENUE CHANNELS GROWING VALUE FOR STAKEHOLDERS
Our largest markets are UK,
Germany, France, Italy and
Spain. We have stores in a
further six countries and a key
distributor in Eastern Europe.
The vast majority of our
revenues are in USA. We also
have a small presence in
Canada and a new distributor
agreement in Latin America.
Our largest markets here
are Japan, South Korea
and China. We also have a
number of distributor markets,
the largest being Australia.
£377.5m
revenue
2025: £384.2m
2026
Where we operate today:
2027
Moving towards a market-based model.
We will focus on getting closer to our consumers,
organising around markets with clear accountability
for performance and growth. By structuring the
business market by market, we will curate the
channel mix to best reflect consumer preferences,
enabling sharper decision-making and more
responsive execution.
p.26
p.42
£278.4m
revenue
2025: £288.5m
£109.0m
revenue
2025: £114.9m
OWNERS
Long-term business success drives
share price appreciation together
with a progressive dividend policy.
OUR PEOPLE
Ongoing training and development within a
supportive and inclusive working environment,
enabling people to do their life’s best work.
CONSUMERS
Being able to buy a timeless, beautifully
crafted, durable product for a fair price.
PARTNERS
Working with an iconic, global brand that
resonates strongly with their consumers.
SUPPLIERS
Association with a strong, responsible brand
that can generate long-term demand growth.
ENVIRONMENT & COMMUNITIES
Reducing our environmental impact and
supporting our communities to leave things
better than we found them.
EMEA
AMERICAS
APAC
Ambition
To be the world’s most desired
premium footwear brand
STRATEGIC REPORT
19
DR. MARTENS PLC ANNUAL REPORT 2026

STRATEGY
Levers
for
growth
20
DR. MARTENS PLC ANNUAL REPORT 2026

Ambition
To be the world’s most desired
premium footwear brand
Consumer
Engage more consumers
+ Lead marketing with product, grounded in comfort, craft and confidence
+ Deliver a seamless omni-channel experience tailored to each consumer
+ Build post-purchase engagement to increase purchase frequency and consumer spend
p.22
Markets
Curate market-right distribution
+ Expand B2B through long-term product and
marketing partnerships with top-tier accounts
- BuildadifferentiatedDTCfootprinttoelevate
the brand, aligning operating models to
each market
+ Enter new growth markets with capital-light
distribution models
Product
Drive more purchase occasions
+ Reinforce premium positioning of our icons
through elevated collections
+ Manage hero product families to optimise
newness across diverse wearing occasions
+ Extend our offer in sandals, bags and other
adjacent categories
+ Innovate to enhance comfort, lightness
and sustainability
Organisation
Simplify the operating model
+ Simplify how we work to drive efficiency, scale and speed
+ Optimise the cost base to support strategic priorities
+ Build a culture of excellence, care and accountability, strengthening organisational
clarity, talent development and disciplined execution on consumer spend
p.28
Medium-term targets
Over the medium term we expect to deliver sustainable, profitable
revenue growth above the rate of the relevant footwear market,
with operating leverage driving a mid to high-teens EBIT margin,
and underpinned by strong cash generation.
WE HAVE FOUR LEVERS FOR GROWTH:
p.26 p.24
STRATEGIC REPORT
21
DR. MARTENS PLC ANNUAL REPORT 2026

HOW WE’VE PERFORMED
Off-price USA wholesale pairs declined 31%
Strong Full Price DTC performance in Americas +14% and APAC +15%
returning to disciplined promotional windows
UtilisedourCustomerDataPlatform(CDP)toimprovepromotionalefficiency
Our 2026 objective
Reduce the reliance on discounted pairs in Americas wholesale
Engage more
consumers
- Lead marketing with product, grounded
in comfort, craft and confidence
- Deliver a seamless omni-channel experience
tailored to each consumer
- Build post-purchase engagement to increase
purchase frequency and consumer spend
STRATEGY IN ACTION
Consumer
22
DR. MARTENS PLC ANNUAL REPORT 2026

Americas DTC Full Price revenue up
14%
Progress driven
by USA
We’ve seen good performance in our USA
business and healthy confidence from
Americas wholesale partners, with fewer
discounted pairs, improved visibility and
a healthy, higher-quality order book.
What began as an Americas-led effort to
reduce discounted pairs through wholesale
quickly broadened into a Group-wide
objective. This shift has strengthened our
Full Price mix, helped by a deliberate move
away from promotional-led activity outside
of key clearance windows and reinforced by
product-first storytelling across tailored
omni-channel experiences.
We also achieved a good Full Price DTC
performance in our APAC markets, up 15%.
EMEA Full Price DTC revenues were down
13%. With USA and APAC markets now
addressed, growing Full Price mix in our
largest EMEA markets is a priority for FY27.
The benefit of CDP
Stronger post-purchase engagement is
improving consumer journeys, increasing
purchase frequency and spend, and driving
higher consumer lifetime value, which we
can now track and optimise with greater
intent through our CDP.
The CDP allows us to segment
consumers more intelligently, for example
by distinguishing ‘full-price shoppers’
from ‘bargain hunters’, to target each
group with relevant offers. For example,
a recent win-back email campaign achieved
significant ROI and reactivation rates
for lapsed consumers, demonstrating
the power of targeted promotions.
By leveraging the CDP’s consumer profiles
in marketing campaigns, we are increasing
promotional effectiveness. Using first-party
audience data to build lookalike audiences
enabled us to significantly reduce
advertising spend compared with previous
broad campaigns that relied on third-party
data, while maintaining performance. We are
therefore able to reach the right consumers
with less spend.
CDP-driven personalisation within
our promotional activity is generating
uplifts in sales. Targeting consumers with
personalised content, such as tailored
newsletters and VIP offers, delivered
significant incremental revenue. These
outcomes illustrate how CDP insights
make our promotions more effective,
driving higher ROI and meaningful
revenue lift with the same or lower spend.
Group DTC Full Price revenue up
1%
Group DTC Full Price mix up
3%pts
STRATEGIC REPORT
23
DR. MARTENS PLC ANNUAL REPORT 2026

STRATEGY IN ACTION CONTINUED
Product
HOW WE’VE PERFORMED
Tripled contribution of product families Buzz, Zebzag and Lowell,
from 3% to 9% of pairs
19% revenue increase in shoes, with growth broad-based across
multiple silhouettes
Strong collaborations throughout FY27
Our 2026 objective
Drive pairs growth in product families such as Buzz, Zebzag and Lowell
Drive more
purchase occasions
- Reinforce premium positioning of our icons through
elevated collections
- Manage hero product families to optimise newness
across diverse wearing occasions
- Extend our offer in sandals, bags and other
adjacent categories
- Innovate to enhance comfort, lightness and sustainability
Lowell Leather Moc Toe Shoes
24
DR. MARTENS PLC ANNUAL REPORT 2026

2026
2025
2024
2023
Boots Shoes Sandals Bags & other
68%
52%
57%
61%
20%
31%
26%
22%
9%
11%
12%
12%
3%
6%
5%
5%
During the year, performance was driven by
continued strength in shoes, in line with our
strategy to diversify the range. This has been
supported by a disciplined approach to range
architecture, including a c.45% reduction in
SKUs since 2022, creating space to introduce
new product families with distinct consumer
benefitsandofferconsumersgenuinechoice.
Bags and small leather goods performed
well and represent a clear growth priority,
supporting diversification of the portfolio
and increased basket size. Sandals remain
an important opportunity; however, further
innovation is required to strengthen the
proposition and unlock their full potential
in the seasons ahead.
Product families
Buzzisourfashion-ledcasualfamily,offering
consumers a bold and contemporary
everyday style inspired by our 90s archive.
The Buzz shoe became our top-performing
new shoe in H1, and the Buzz Hi became
the bestselling new product in H1 EMEA
DTC. In H2 we expanded the Buzz range
into boots, with good consumer reaction.
Lowell serves consumers who want a
more crafted and elevated aesthetic with
premium finishes. The Lowell silhouette is
highlighted with design details that speak
to its workwear origins, including puritan
stitch construction, a leather heel tab and a
padded collar. Only 12 months after launch,
Lowell was already a top five shoe in EMEA
in H1. The Lowell Chukka Moc Toe boot
was introduced in AW25 to further expand
the Lowell range.
Our Zebzag family is built on a cushioned,
lightweight sole engineered for instant,
all-day comfort, purposefully designed
to meet the demands of modern life with
standout craft, durability and everyday
ease. What began with our Zebzag
Mules has grown into a range of easy-on
silhouettes, from platform sandals to the
Zebzag Laceless boot, which launched
in September and is performing well.
The changing shape of our range
Collaborations
Working in collaboration with influential,
world-class designers and craftmakers is
an important part of building brand desire
and across FY26 we worked with exceptional
collaboration partners. We celebrated the
return of our successful collaboration with
Rick Owens, reconsidering the 1460 Boot
silhouette with exaggerated proportions.
Our launch with New York’s MadeMe focused
on strengthening the Buzz franchise. Our
partnership with Marc Jacobs Kiki Corran
blended their iconic Kiki upper language with
our Corran outsole. To elevate our icons we
collaborated with a number of world-class
partners, with our Metallica collaboration
bringing together fans of the Metallica and
Dr. Martens to create a collection inspired
by iconic Metallica artwork.
“Collaborations represent
where we’re heading –
connected to our roots
while exploring new
creative territory with
partners who challenge
and inspire us, and those
who share the same
commitment to craft.”
CARLA MURPHY
CHIEF BRAND OFFICER
Our evolving product mix reflects our
strategy to drive purchase occasions, and
we expect shoes, sandals and bags to
continue to grow in share in the years ahead.
Zebzag Laceless Slip On Leather Boots Buzz 5-Eye Leopard Shoes
Steel Toe Rick Owens Boots
STRATEGIC REPORT
25
DR. MARTENS PLC ANNUAL REPORT 2026

Mexico
Peru
Colombia
Costa Rica
Argentina
Uruguay
STRATEGY IN ACTION CONTINUED
Markets
New distribution agreements
Accelerating expansion plans with partners
LATIN AMERICA:
Significant growth region
At the end of FY25 we re-entered Latin America
through a partnership with Crosby, with the
agreement initially covering Argentina, Chile,
Mexico and Paraguay. During FY26 we:
- Opened our first mono-branded stores in
Buenos Aires (August) and Santiago (October)
- Expanded the agreement to include Colombia,
CostaRica,PeruandUruguay(inQ3).
This partnership significantly increases brand
visibility and consumer access across the region,
underlining the scalability of our capital-light model.
Chile
Paraguay
HOW WE’VE PERFORMED
Signed distribution agreement in Latin America and UAE
Accelerated our expansion plans with our partner in the Philippines
Begun refining the model in China and Italy with the opening
of partner stores
Our 2026 objective
Open in new markets through a capital-light structure
Curate market-right
distribution
- Expand B2B through long-term product and
marketing partnerships with top-tier accounts
- Build a differentiated DTC footprint to elevate the
brand, aligning operating models to each market
- Enter new growth markets with capital-light
distribution models
Market-right distribution in practice
Ourstrategyrecognisesthatmarketsdiffer,sowecuratetheright
distribution approach for each, ensuring the brand shows up in the
mosteffectiveway.Insomeregions,suchasinlandareasoftheUSA,
wholesaleisthemostefficientroutetoreachconsumers,whileinothers,
like Japan, we predominantly reach consumers today through DTC.
26
DR. MARTENS PLC ANNUAL REPORT 2026

Accelerating expansion
Strong consumer demand encouraged us and
our long-standing partner to accelerate our
original store growth plan. During FY26 three
partner stores were opened, reflecting the
market’s appetite for our blend of heritage, style
and durability. This expansion reinforces our
presence and improves accessibility.
Strengthening presence
in a key European market
We continued to grow across owned, franchise and
wholesale channels, ensuring a consistent, premium
consumer experience. This year we expanded our
footprint through capital-light partners, including Italy’s
firstfranchisestoreopeninginPompeii.Wecontinue
toseesignificantopportunitytoelevateourbrand
in Italy through deeper consumer engagement and
improved marketplace positioning.
Entering a new region
This year marked our first-ever entry into
the UAE. We signed a distribution agreement
with Beside Group, a partner with deep
regional expertise and a well-established
retail network. We will launch and scale
our presence via wholesale initially, with
mono-brand stores to follow, allowing us to
grow in a capital-light, market-right manner.
Working with partners
In China, where we have seven directly
operated stores mainly in Shanghai,
we have begun working with partners to
open mono-branded stores in other cities.
Two stores opened in FY26, in Chongqing
and Hangzhou, with more in the pipeline.
UAE
China
Italy
Philippines
Most markets sit somewhere in between, and our capital-light
partnerships give us the agility to flex accordingly, whilst protecting
the brand and minimising capital investment.
Over the past year, this tailored approach delivered good progress.
By enabling consumers to buy where and how they want, we
expanded our reach, strengthened brand presence and unlocked
high-potential markets in a way that will accelerate growth and
support long-term, profitable international expansion.
STRATEGIC REPORT
27
DR. MARTENS PLC ANNUAL REPORT 2026

STRATEGY IN ACTION CONTINUED
Organisation
HOW WE’VE PERFORMED
Restructured the organisation, moving from a regional structure to individual markets
Creation of streamlined Executive Team
Leveraged our Global Technology Centre in India
Embedded our Supply and Demand Planning System
Our 2026 objective
Simplify our operating model
Simplify the
operating model
- Simplify how we work to drive efficiency,
scale and speed
- Optimise the cost base to support
strategic priorities
- Build a culture of excellence, care and
accountability, strengthening
organisational clarity, talent
development and disciplined execution
28
DR. MARTENS PLC ANNUAL REPORT 2026

Reorganising
our business
In Q4 we undertook a reorganisation,
replacing our regional structure with a
market-led model that gives clearer
accountability, faster decision-making and a
deeper connection to consumers. This work
was done carefully and considerately, with the
new structure in place for the start of FY27.
New General Managers (GMs) will lead key
markets with clear accountability, responsible
for profitable, sustainable growth and for
bringing the global brand strategy to life
locally. This shift elevates the role of GMs
as the key link between global strategy and
local execution.
GTC
The Global Technology Centre (GTC) in
India is a strategic hub that brings together
75% of our technology organisation in one
location to improve efficiency, scalability
and long-term capability. By centralising
teams in Bangalore, we can access a
strong local talent pool, reduce reliance on
contractors and strengthen execution across
core platforms and services. Over the next
few years, the GTC will help us deliver at
a faster pace, make better use of existing
investments and build a more robust
foundation to support key priorities such
data usage, insights and digital innovation.
SUPPLY AND DEMAND PLANNING
The final element of our modern systems
architecture, the Supply and Demand
Planning System, went live as scheduled
in the summer. This new, modern system
is already delivering greater visibility and
accuracy over our inventory forecasting,
improving availability of product whilst
optimising working capital. Benefits are
anticipated to build over time as integrated
capabilities mature.
Engagement of culture
It is the combination of our brand, our
products and our people that make our
business so unique. We continue to
invest in our people experience and
talent development so that we create an
environment where people can do their life’s
best work for our consumers in a rewarding,
engaging and supportive environment.
FY26 saw us reorganise our people and
teams to enable us to deliver the new
strategy. Through the year, and particularly
during the reorganisation, we placed a
particular focus on supporting our people,
two-way engagement and strong
communication.
Read more about our culture and engagement
on p.108
For information on how the Board considered
our people in decision-making see p.110
71%
Kept well informed
(+6%)
78%
Confidence of store teams
going into peak
84%
Proud to work for DMs (+3%)
80%
Feel supported by my manager
STRATEGIC REPORT
29
DR. MARTENS PLC ANNUAL REPORT 2026

Meet the
Executive Team
STRATEGY IN ACTION CONTINUED
30
DR. MARTENS PLC ANNUAL REPORT 2026

We have streamlined the leadership team
reporting into CEO Ije Nwokorie, reducing
the number of direct reports to improve
speed of decision-making and accountability.
The Executive Team consists of:
Chief Executive Officer
IJE NWOKORIE
Setting the Company’s strategy, leading the Executive Team and driving disciplined
execution to deliver performance with the consumer and brand at the core.
Chief Financial Officer
GILES WILSON
Pulling together the strategic direction, enabling systems and funding to deliver a world-class
operating platform. Technology also now reports into the CFO.
Chief Brand Officer
CARLA MURPHY
Ensuring the brand is the connective tissue of all we do. Product, Marketing, Customer Experience
and Sustainability collectively form the brand organisation.
Chief Operations Officer (Interim)
ANNA DUFFIET
Driving the operational excellence that enables and underpins our business model.
Oversees supply chain, logistics and distribution.
Chief Commercial Officer
MIKE STOPFORTH
A new global role ensuring we deepen our connection to our consumers across all markets.
The market GMs report into the CCO, alongside the President of Growth and Partner Markets.
President of Americas
PAUL ZADOFF
Responsible for our biggest market with a wider remit for our corporate activities in this important region.
Chief People Officer
BRIDGET JOLLIFFE
Creating an environment of excellence and care, enabling people to do their life’s best work.
Chief Legal Officer and Company Secretary
KATHERINE BELLAU
Protecting the Dr. Martens brand and supporting all of our people in doing business the right way.
STRATEGIC REPORT
31
DR. MARTENS PLC ANNUAL REPORT 2026

profit
growth
FINANCE REVIEW
Driving
GILES
WILSON
Chief Financial Officer
32
DR. MARTENS PLC ANNUAL REPORT 2026

Total revenue was £764.9m reported, or £776.3m Constant
Currency (CC), in line with guidance and representing a decline
of 2.9% or 1.4% CC. The focus on Full Price sales and reducing
clearance activity was a headwind to DTC revenues, as expected,
resulting in a decline of 5.8% (4.2% CC). Wholesale revenues grew
by 2.5% (3.7% CC), with growth seen across most major markets.
Adjusted profit before tax
1
was £55.0m (FY25: £34.1m) and
£54.2m CC, up 61.3% or 58.9% CC. The improvement was driven
by stronger margins year-on-year, with COGS and Opex
1
tightly
managed and benefitting from the cost saving activities in FY25.
Within Opex our continued tight focus on costs drove a year-on-year
reduction in non-demand-generating spend of 6.0%, whilst spend
on demand generation was broadly flat (down 0.2% reported or up
1.8% CC). Adjusted basic earnings per share
1
was 4.2p (4.1p CC),
representing significant growth compared to 2.4p in FY25.
Results – at a glance
£m
FY26
Reported
FY26
CC
1,2
FY25
Reported
% change
Reported
% change
CC
1,2
Revenue Ecommerce 244.4 248.7 268.3 -8.9% -7.3%
Retail 236.8 240.5 242.4 -2.3% -0.8%
DTC 481.2 489.2 510.7 -5.8% -4.2%
Wholesale
3
283.7 287.1 276.9 2.5% 3.7%
Group 764.9 776.3 787.6 -2.9% -1.4%
Gross margin 506.0 512.8 511.7 -1.1% 0.2%
Opex
1
(359.0) (365.5) (378.4) -5.1% -3.4%
Adjusted EBIT
1
79.3 78.7 60.7
Currency gains/(losses) 0.9 (0.9) (3.1)
Impairmentofnon-financialassets (4.2) (4.1) (4.3)
Exceptional costs
1
(12.1) (12.5) (16.3)
Investment in transformation
1
(6.9) (6.9) –
EBIT
1
57.0 54.3 37.0
Adjustedprofitbeforetax
1
55.0 54.2 34.1
Profitbeforetax 32.7 29.8 8.8
Profitaftertax 23.8 4.5
Adjusted basic earnings per share (p)
1
4.2 4.1 2.4
Basic earnings per share (p) 2.5 2.2 0.5
Dividend per share (p) 2.55 2.55
Key metrics Pairs sold (m) 10.2 10.5 -2.5%
No. of stores
4
240 239
DTC mix % 62.9% 63.0% 64.8% -1.9pts -1.8pts
Gross margin % 66.2% 66.1% 65.0% 1.2pts 1.1pts
Adjusted EBIT margin %
1
10.4% 10.1% 7.7% 2.7pts 2.4pts
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
2. Constant currency applies the prior period exchange rates to current period results to remove the impact of FX.
3. Wholesale revenue including distributor customers.
4. Directly-operated stores on streets and malls operated under arm’s length leasehold arrangements.
In order to assist shareholders’ understanding of the performance
of the Group, the narrative below is focused on the adjusted
performance for the period, using several non-GAAP and Alternative
Performance Measures (APMs); in particular adjusted EBIT
1
,
adjusted profit before tax
1
and adjusted basic earnings per share
1
.
The Directors consider these adjusted measures to be relevant
as they provide a clearer view of the Group’s ongoing operational
performance. They also reflect how the business is managed and
measured on a day-to-day basis, aid comparability between periods
and, by excluding the effect of significant non-cash accounting
adjustments, more closely correlate with the cash and working
capital position of the Group.
The adjusted measures are before certain exceptional costs
1
,
investment in transformation as well as impairment of non-financial
assets and currency gains/(losses), as these are significant
non-cash accounting adjustments. A glossary and a reconciliation
of these APMs to statutory figures can be found at the end of this
report on pages 227 to 229.
STRATEGIC REPORT
33
DR. MARTENS PLC ANNUAL REPORT 2026

FINANCE REVIEW CONTINUED
PERFORMANCE BY REGION
£m FY26 FY25
% change
Reported
% change
CC
1
Revenue: EMEA 377.5 384.2 -1.7% -3.7%
Americas 278.4 288.5 -3.5% 1.1%
APAC 109.0 114.9 -5.1% -0.3%
764.9 787.6 -2.9% -1.4%
EBIT
1
: EMEA 78.7 74.4 5.8%
Americas 25.0 9.4 166.0%
APAC 17.2 15.0 14.7%
Support costs
2
(63.9) (61.8) 3.4%
57.0 37.0 54.1%
Adjusted EBIT
1
: EMEA 82.5 7 7. 3 6.7%
Americas 27.0 13.6 98.5%
APAC 18.5 16.0 15.6%
Support costs
2
(48.7) (46.2) 5.4%
79.3 60.7 30.6%
EBIT
1
margin by region: EMEA 20.8% 19.4% 1.4 pts
Americas 9.0% 3.3% 5.7pts
APAC 15.8% 13.1% 2.7pts
Total
3
7.5% 4.7% 2.8pts
Adjusted EBIT
1
margin by region: EMEA 21.9% 20.1% 1.8pts
Americas 9.7% 4.7% 5.0pts
APAC 17.0% 13.9% 3.1pts
Total
3
10.4% 7.7% 2.7pts
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
2. Support costs represent Group-related support costs not directly attributable to each region’s operations and including Group Finance, Legal, Group HR, Global Brand and Design,
Directors, Global Supply Chain and other Group-only related costs and expenses.
3. Total EBIT margins are inclusive of support costs.
EMEA Revenue declined 1.7% to £377.5m, or 3.7% CC. Wholesale
revenue grew by 9.8% (7.6% CC), supported by delivery of a
stronger Autumn/Winter orderbook. Our EMEA DTC performance
was impacted by consumers participating in clearance against a
challenging consumer backdrop; this was particularly seen in UK
and DACH. As a result, EMEA DTC declined by 8.0% (9.9% CC),
with retail and ecommerce down 6.3% and 9.8% respectively
(8.3% and 11.5% CC). Full Price DTC mix declined 4pts; growing
Full Price mix in our largest EMEA markets is a priority for FY27.
EMEA adjusted EBIT
1
was £82.5m (FY25: £77.3m) due to tight
management of costs.
Americas Revenue declined 3.5% to £278.4m, however grew
1.1% in CC. DTC revenue declined by 3.7% (+1.1% CC), with
ecommerce revenues declining 7.9% (3.4% CC) with a strong
performance in Full Price being offset by the headwind of planned
reduced clearance activity. Americas retail grew 2.9% (8.2% CC),
with growth in CC in all quarters driven by higher footfall. Americas
wholesale revenue declined 3.1%, however grew 1.2% CC,
benefitting from good growth in both AW25 and SS26 orderbooks.
The wholesale performance was also impacted by the headwind of
aone-offlargeoff-pricewholesaledealinFY25whichmademinimal
profit contribution but served to right-size inventory. Excluding
this the underlying wholesale performance was stronger.
Americas adjusted EBIT
1
was £27.0m (FY25: £13.6m), driven
by improved gross margin, favourable FX movements and tight
management of costs.
APAC Revenue declined by 5.1% to £109.0m, down 0.3% CC. DTC
revenues declined 3.4% but grew 1.3% CC. South Korea Retail grew
25.4% (34.2% CC), driving total APAC retail growth of 0.9% (6.2%
CC). Japan, our largest market in APAC, grew ecommerce 12.6%
(18.1% CC), while China and South Korea were again impacted by
a significant planned reduction in clearance activity, contributing to
a total ecommerce decline in APAC of 8.9% (5.0% CC). Wholesale
was down 9.5% (4.3% CC) with an expected reduction in revenues
to our Australian distributor together with our exit from several
third-party ecommerce websites.
APAC adjusted EBIT
1
increased to £18.5m (FY25: £16.0m), driven
by improved gross margin and tight management of costs.
PERFORMANCE BY CHANNEL
Revenue decreased by 2.9% or 1.4% CC, driven by a decline in
DTC revenue of 5.8% or 4.2% CC. The focus on Full Price revenue
resulted in DTC Full Price revenue growing 0.6% and Full Price mix
increasing by 3pts, with a strong Full Price performance in USA and
APAC and a decline in EMEA Full Price, where we have more work
to do. Wholesale revenues increased by 2.5% or 3.7% CC.
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
34
DR. MARTENS PLC ANNUAL REPORT 2026

Volume, represented by pairs sold, decreased 2.5% to 10.2m
pairs with wholesale down 0.7% and DTC down 4.6% to 4.4m pairs.
The volume decline (of 2.5%) was greater than the CC revenue
performance (of 1.4%) due to the increase in ASP as a result of the
Full Price focus. This dynamic was most pronounced in Americas.
Full Price DTC pairs were up 2.4%, with Americas again the
standout performance, with Full Price DTC pairs up 16.5%.
The Americas pairs performance was despite a one-off large
off-price wholesale deal in USA completed in Q4 last year.
Ecommerce revenue was down 8.9% or 7.3% CC. This
performance was impacted by the planned reduction in clearance
activity, particularly in Americas, China and South Korea, with
all regions seeing a significant managed decline in discounted
ecommerce revenue. This was partially offset by an increase in
Full Price ecommerce revenue in Americas and APAC, however
in EMEA the headwind from consumers participating in clearance
against a challenging consumer backdrop resulted in Full Price
revenue decline.
Retail revenue declined 2.3% or 0.8% CC. In EMEA retail declined
by 8.3% CC, with weak footfall across all markets. We saw good
growth in America and APAC, up 2.9% and 0.9% respectively (8.2%
and 6.2% CC), with South Korea the standout market delivering
double-digit growth in all quarters and 34.2% CC for FY26. During
the period we opened 19 new stores and closed 18 stores to end
the period with 240 directly-operated stores. The 18 stores closed
duringtheperiodwereinmultiplemarketsandreflectthedisciplined
approach to store reviews in line with the new retail strategy.
Wholesale revenue was up 2.5% or 3.7% CC with both EMEA and
Americas delivering positive growth as AW25 order books were
fulfilledtowholesalecustomers,andstrongSS26orderbookgrowth
in Americas. APAC declined 4.3% CC in line with expectations.
RETAIL STORE ESTATE
During the period, we opened 19 (FY25: 17) new directly-operated
stores (via arm’s length leasehold arrangements) and closed 18
stores (FY25: 17), of which two were relocations.
Directly-operated stores
30 March
2025 Opened Closed
29 March
2026
EMEA: UK 34 2 (3) 33
Germany 17 2 (1) 18
France 18 1 – 19
Italy 14 – – 14
Spain 6 – (2) 4
Other 14 – – 14
103 5 (6) 102
Americas: 59 5 (7) 57
APAC: Japan 46 4 (2) 48
China 7 3 (3) 7
South Korea 17 1 – 18
Hong Kong 7 1 – 8
77 9 (5) 81
Total directly-operated
stores 239 19 (18) 240
The Group also trades from 15 (FY25: 20) concession counters
in department stores in South Korea and a further 96 (FY25: 88)
mono-branded franchise stores around the world as follows below,
with the first stores opening in Italy, Argentina, Chile and China
during the period.
Franchise and
partner stores
30 March
2025 Opened Closed
29 March
2026
EMEA: Italy – 1 – 1
– 1 – 1
Americas: Argentina – 1 – 1
Chile – 1 – 1
Canada 4 – – 4
4 2 – 6
APAC: Japan 24 1 – 25
China – 2 – 2
Australia 22 – (1) 21
New Zealand 5 – – 5
Taiwan 14 – (2) 12
Indonesia 10 2 (1) 11
Thailand 5 – – 5
Malaysia 2 1 – 3
Philippines 2 3 – 5
84 9 (4) 89
Total mono-branded franchise
and partner stores 88 12 (4) 96
ANALYSIS OF PERFORMANCE BY HALF
H1 revenue declined by 0.8% but increased by 0.8% CC, supported
by DTC growth in the Americas and APAC. In H2, trading conditions
became more competitive, increasing the consumer participation
of clearance, particularly in UK and DACH. This, combined with
stronger prior period comparatives in H2 than H1 resulted in revenue
declining by 4.3% (3.0% CC) to £442.9m (FY25 H2: £463.0m).
The reduction was driven by lower ecommerce revenue across
all regions in H2 and the headwind of a large off-price Americas
wholesale deal in FY25. These headwinds were partly offset
by retail growth in the Americas and APAC, both up 2.9% CC in H2.
Wholesale performance was stronger in H2 than H1, led by EMEA,
which increased by 19.3% (16.0% CC).
H1 FY26 H2 FY26
Reported CC Reported CC
Total Revenue -0.8% 0.8% -4.3% -3.0%
Region: EMEA -2.3% -3.2% -1.3% -4.1%
Americas 1.8% 6.3% -7.0% -2.2%
APAC -1.9% 1.5% -7.4% -1.5%
Channel: Ecommerce -7.3% -5.1% -9.7% -8.4%
Retail 3.0% 4.8% -5.8% -4.4%
DTC -1.9% 0.1% -7.9% -6.6%
Wholesale
1
0.6% 1.8% 4.4% 5.6%
1. Wholesale revenue including distributor customers.
STRATEGIC REPORT
35
DR. MARTENS PLC ANNUAL REPORT 2026

FINANCE REVIEW CONTINUED
ANALYSIS OF PERFORMANCE BY QUARTER
Revenue performance by quarter was uneven, reflecting a combination of deliberate trading decisions and the shape of comparatives.
Q2 showed an improvement from Q1 across EMEA and APAC, driven primarily by a strong retail performance which grew 8.7% CC in Q2,
compared to 0.7% CC growth in Q1. Q3 was weaker against a more challenging comparative, with a weaker EMEA ecommerce performance,
while US ecommerce remained resilient, delivering a third consecutive quarter of growth. Retail continued to show a strong performance with
both Americas and APAC retail markets growing in Q3 and Q4. Wholesale grew in all quarters on a CC basis, with strong growth in EMEA
and Americas wholesale performance, more than offsetting the impact of a large off-price US wholesale deal in Q4 last year.
Q1 Q2 Q3 Q4
Reported CC Reported CC Reported CC Reported CC
Total Revenue -2.3% 0.7% 0.0% 0.9% -3.1% -2.7% -5.9% -3.5%
Region: EMEA -7.9% -7.2% 0.4% -1.3% -3.0% -6.0% 1.1% -1.3%
Americas 5.7% 11.9% -0.1% 3.4% -1.6% 2.2% -13.0% -7.2%
APAC -2.8% 0.0% -1.2% 2.7% -7.4% -2.7% -7.4% 0.0%
Channel: Ecommerce -4.9% -1.8% -9.1% -7.7% -6.8% -6.1% -14.1% -11.9%
Retail -2.0% 0.7% 7.7% 8.7% -7.3% -7.0% -3.5% -0.7%
DTC -3.3% -0.5% -0.7% 0.5% -7.0% -6.5% -9.3% -6.8%
Wholesale
1
0.7% 4.2% 0.6% 1.2% 9.3% 9.5% 0.1% 2.3%
1. Wholesale revenue including distributor customers.
PROFITABILITY ANALYSIS
Gross margin improved by 1.2pts to 66.2% or by 1.1pts CC driven
by the benefit of the increase in Full Price mix across US and APAC
partially offset by the promotional EMEA market, combined with
continued good control of COGS across the Group, particularly
through freight savings.
Opex
1
declined by 5.1%, or £19.4m, to £359.0m. Opex
1
not linked
to demand generation was tightly controlled across the business
and benefited from the cost actions taken in FY25; as a result
non-demand generating opex declined 6% year-on-year. Demand
generating opex remaining broadly flat, down 0.2%.
All IEEPA-related US tariffs included within Opex have been
considered an exceptional cost due to their magnitude and unusual
nature, with any future refunds to be considered exceptional income.
EBITDA
1
increased by 9.4% to £128.0m (FY25: £117.0m), with
reduced revenues offset by tight cost control.
EBIT
1
improved by 54.1% to £57.0m (FY25: £37.0m) as a result
of the increase in EBITDA and currency gains of £0.9m (FY25:
currency losses of £3.1m), and lower depreciation and amortisation
of £68.4m (FY25: £72.5m).
Profit after tax is analysed in the following table from EBITDA:
£m FY26 FY25
EBITDA
1
128.0 117.0
Depreciation and amortisation (68.4) (72.5)
Impairment (4.2) (4.3)
Other gains/(losses) 0.7 (0.1)
Currency gains/(losses) 0.9 (3.1)
EBIT
1
57.0 37.0
Add back: exceptional costs and adjusting
items
1
22.3 23.7
Adjusted EBIT
1
79.3 60.7
Net bank interest costs (17.7) (21.1)
Interest on lease liabilities and unwind of
provisions (6.6) (7.1)
Profit before tax 32.7 8.8
Add back: exceptional costs and adjusting
items
1
22.3 25.3
Adjusted profit before tax
1
55.0 34.1
Tax (8.9) (4.3)
Profit after tax 23.8 4.5
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
36
DR. MARTENS PLC ANNUAL REPORT 2026

Depreciation and amortisation charged in the period was £68.4m
(FY25: £72.5m) and is analysed as follows:
£m FY26 FY25
Amortisation of intangibles
1
6.3 6.1
Depreciation of property, plant and equipment
2
13.3 15.0
19.6 21.1
Depreciation of right-of-use assets
3
48.8 51.4
Total 68.4 72.5
1. Mainly represented by IT-related spend with the average useful term of 5 to 15 years.
2. Mainlyrepresentedbyofficeandstorefit-outcostswithausefultermof3to15years.
3. Mainly represented by depreciation of IFRS 16 capitalised leases with the average useful
term remaining of 2.9 years and 271 properties (FY25: 3.2 years and 267 properties).
FOREIGN CURRENCY
Dr. Martens is a global brand selling to consumers across the world
inmanydifferentcurrencieswiththeFinancialStatementsreported
in GBP. Foreign currency amounts in the Profit or Loss account
are prepared on an average actual currency rate basis for the period.
These exchange rates are calculated monthly and applied to
revenue and costs generated in that month, such that the actual
performance translated across the period is dependent on monthly
trading profiles as well as movement in currency exchange rates.
To aid comparability of underlying performance, we have also
calculated constant currency
1
movements across the Profit and
Loss account, which is calculated by applying the prior period
exchange rates to current period results to remove the impact of FX.
Exchange rates mainly impacting the Group are GBP/USD,
GBP/EUR and GBP/JPY. The following table summarises average
exchange rates used in the period:
GBP/USD GBP/EUR GBP/JPY
FY26 FY25 % FY26 FY25 % FY26 FY25 %
H1 1.34 1.28 4.7% 1.17 1.18 -0.8% 196 195 0.5%
H2 1.34 1.27 5.5% 1.15 1.20 -4.2% 208 194 7.2%
FY 1.34 1.28 4.7% 1.16 1.19 -2.5% 202 194 4.1%
The Group takes a holistic approach to exchange rate risk,
monitoringexposuresonaGroup-wide,netcashflowbasis,seeking
to maximise natural offsets wherever possible. While COGS
purchases for the Group are predominantly denominated in USD,
currency risk is partially offset from USD revenues earned in the
Americas and from distributor revenues, which are also largely USD
denominated. Where a net foreign currency exposure is considered
material, the Group seeks to reduce volatility from exchange
movements by using derivative financial instruments. During the
period, a £1.4m loss (FY25: £3.8m gain) was recorded in revenues
related to derivatives partially hedging the net EUR inflows.
Retranslation of foreign currency denominated monetary assets
and liabilities in the period resulted in a currency gain of £0.9m
(FY25: loss of £3.1m). This was predominantly due to the
revaluation of external purchase balances following the
depreciation of USD against GBP.
INTEREST
The Group’s exposure to movements in interest rates arises
primarily from cash investments, borrowings and IFRS 16 lease
liabilities. Total Group net interest costs for the period were £24.3m,
£3.9m lower than the prior year (FY25: £28.2m). This reduction
was mainly driven by lower interest on lease liabilities, together with
reduced Term Loan interest and Revolving Credit Facility (RCF)
non-utilisation fees, reflecting lower average principal amounts
following the refinancing completed in November 2024. In addition,
£1.6m of unamortised costs related to fees on the prior debt were
accelerated and recognised in FY25.
ADJUSTING ITEMS
1
In January 2026, the Group internally announced a reorganisation
programme with operating model changes effective from 1 April
2026, moving from a regions-based to a market-centric operational
model. The move to a market-centric model will enable a consumer-
first focus and ensure the business is organised to enable delivery
of the new strategy. Investment in transformation costs have been
included within adjusting items
1
as a new category.
In FY25, the Group announced it would be undertaking a cost action
plan, through operational efficiency and design, better procurement
and operational streamlining. We saw some benefit in FY25, with the
full benefit of annualised savings realised in FY26. In February 2025,
the Group commenced a project to change and improve the Global
Technology organisation and capability through the establishment
of a new technology centre in India. The costs of these projects have
been classed as exceptional.
In the period, the Group incurred exceptional costs of £12.1m
(FY25: £16.3m), £9.9m of which related to IEEPA-related US
tariffs following the US Supreme Court judgment, £0.8m Director
joining costs relating to the CEO and CFO, £0.4m in relation to
establishment of the Global Technology Centre in India, and £1.0m
pension buy-in accounting charges and associated expenses.
Impairmentofnon-financialassets,inrelationto15underperforming
stores globally, currency gains/(losses) along with investment in
transformation are presented as other adjusting items
1
to provide
a clearer view of the Group’s underlying operational performance.
£m FY26 FY25
Included in selling and administrative
expenses
Exceptional costs
1
Director joining costs 0.8 4.6
Cost savings-related costs 0.4 11.7
Pension buy-in accounting charges and
associated expenses 1.0 –
IEEPA-relatedUStariffsfollowingtheUS
Supreme Court judgment 9.9 –
12.1 16.3
Other adjusting items
Investment in transformation 6.9 –
Impairmentofnon-financialassets 4.2 4.3
Currency (gains)/losses (0.9) 3.1
Adjustments to EBIT
1
22.3 23.7
Exceptional costs
1
Accelerated amortisation of fees on debt
refinancing – 1.6
Adjustments to profit before tax 22.3 25.3
Tax charge was £8.9m (FY25: £4.3m charge) with an effective tax
rate of 27.2% (FY25: 48.9%), which is higher than the UK corporate
tax rate of 25.0%. This is driven by non-deductible expenses and
prior year tax adjustments on finalisation of FY25 tax returns.
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
STRATEGIC REPORT
37
DR. MARTENS PLC ANNUAL REPORT 2026

FINANCE REVIEW CONTINUED
Basic earnings per share was 2.5p (FY25: basic and diluted
earnings per share of 0.5p) or 4.2p earnings on an adjusted basis
(FY25: 2.4p). EPS and diluted EPS are similar numbers due to the
minimal dilutive impact of share options on the total diluted share
number. The following table summarises these EPS figures:
FY26 pence
Reported
FY26 pence
CC
1
FY25
pence
Earnings
per share
Adjusted basic
1
4.2 4.1 2.4
Basic 2.5 2.2 0.5
Diluted 2.4 2.1 0.5
CASH FLOWS
£m FY26 FY25
EBITDA 128.0 117.0
Decrease in inventories 23.5 62.7
(Increase)/decrease in debtors (8.8) 6.3
Increase in creditors 5.1 15.3
Total change in net working capital 19.8 84.3
Share-based payments 5.2 7.2
Capex (11.9) (18.7)
Operating cash flow
1
141.1 189.8
Operating cash flow conversion
1,2
110.2% 162.2%
Net interest paid (17.2) (28.1)
Payment of lease liabilities (55.6) (56.2)
Taxation (10.9) (12.2)
Repurchase of shares (6.7) –
Derivatives settlement – (4.0)
Definedbenefitpensionpastservicecost 0.6 –
Proceeds from borrowings – 250.0
Repayment of borrowings – (283.0)
Dividends paid (24.6) (9.5)
Net cash inflow 26.7 46.8
Opening cash 155.9 111.1
Net cash exchange translation (2.3) (2.0)
Closing cash 180.3 155.9
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
2. Adjustedoperatingcashflowconversion
1
is 109.7% (FY25: 149.8%).
Operating cash flow
1
generated an inflow of £141.1m (FY25: inflow
of £189.8m), impacted by positive working capital cash inflows of
£19.8m (FY25: inflow of £84.3m). Cash inflows on inventory were
inflated in FY25 as we cleared down obsolete and fragmented stock
in order to right-size inventory.
Debtors have increased by £8.8m (FY25: £6.3m decrease),
predominantly driven by wholesale customer orders in Q4.
Trade debtor days increased to 61 days (FY25: 58 days), falling
marginally outside the standard 60-day payment terms, driven
by customer mix with a higher proportion of EMEA debtors
(with debtor days at 64) than Americas (with debtor days at 53).
Creditors have increased by £5.1m (FY25: £15.3m) due to the
timing of payments around the reporting date.
Capex was £11.9m (FY25: £18.7m) and represented 1.6% of
revenue (FY25: 2.4%). The breakdown in Capex by category
is as follows:
£m FY26 FY25
Retail stores 7. 2 6.5
Supply Chain 0.1 1.4
IT/Technology 4.6 10.8
11.9 18.7
Net interest paid was £17.2m (FY25: £28.1m), representing a
£10.9m improvement year-on-year. The reduction was primarily
driven by lower debt interest following a change in interest term
periods (from six to three months) and a reduction in the Term Loan
principal amount after the refinancing in November 2024. Further
benefits arose from lower non-utilisation fees reflecting the reduced
principal of the RCF. Cash investment interest increased modestly
due to higher average cash balances, partially offset by lower
interest rates.
Payment of lease liabilities was £55.6m (FY25: £56.2m), lower
than FY25 by £0.6m.
REPURCHASE OF SHARES
Duringtheperiod,theDr.MartensplcEmployeeBenefitTrust(EBT)
was established, for the purpose of purchasing and holding shares
in Dr. Martens plc for subsequent transfer to employees under
the terms of the Group’s share plans. During the period, the Trust
purchased 10,000,000 shares (FY25: nil) for a total cash
consideration of £6.7m.
FUNDING AND LEVERAGE
The Group is funded by internally generated operating cash flows,
bank debt and equity. In November 2024, the Group agreed with
existing and new lenders to refinance its debt facilities, previously
comprising a €337.5m Term Loan and RCF of £200.0m. The facility
consists of a £250.0m Term Loan and RCF of £126.5m for an initial
term of three years, with two one-year extension options, subject
to lender approval.
In April 2026, the lending syndicate approved the Group’s request to
exercise the one-year extension option on both the Term Loan and the
RCF, extending the maturity of these facilities to 14 November 2028,
effective from 1 May 2026. On 30 March 2026, the Group also
cancelled £26.5 million of commitments under the RCF, thereby
reducing the total facility size to £100.0 million. All other terms remain
unchanged. Further details on the capital structure and debt are
given in notes 18 and 22 of the Consolidated Financial Statements.
The facilities are subject to a financial covenant, based on a
Net Debt/LTM EBITDA leverage ratio of <3x which is tested every
six months. The total net leverage test is calculated with a full 12
months of EBITDA (covenant calculation basis) and net debt being
inclusive of IFRS 16 lease liabilities at the Balance Sheet date.
As at 29 March 2026, the Group had total net leverage of 1.4 times
(FY25: 1.8 times).
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
38
DR. MARTENS PLC ANNUAL REPORT 2026

BALANCE SHEET
£m
29 March
2026
30 March
2025
Freehold property 6.5 6.7
Right-of-use assets 131.3 143.2
Otherfixedassets 66.7 76.2
Inventory 160.8 187.4
Debtors 71.2 63.4
Creditors
1
(114.6) (111.4)
Working capital 117.4 139.4
Other
2
- 0 6.0
Operating net assets 328.9 371.5
Pension surplus 3.0 –
Goodwill 240.7 240.7
Cash 180.3 155.9
Bank debt (250.0) (250.0)
Unamortised bank fees 2.4 3.7
Lease liabilities (143.8) (155.4)
Net assets/equity 361.5 366.4
1. Includes bank interest of £2.1m (FY25: £2.4m).
2. Other includes investments, deferred tax assets, income tax assets, income tax
payables, deferred tax liabilities and provisions.
INVENTORY
Inventory declined from £187.4m in FY25 to £160.8m in FY26.
Inventory levels were broadly flat year-on-year in EMEA and
APAC with the reduction being driven by Americas.
£m
29 March
2026
30 March
2025
Inventory (£m) 160.8 187.4
Turn (x)
1
1.5x 1.5x
Weeks cover
2
32 35
1. Calculated as historical LTM COGS divided by average LTM inventory.
2. Calculated as 52 weeks divided by inventory turn.
PENSION SURPLUS
In December 2025, the Trustees purchased a bulk insurance annuity
policy, constituting a buy-in transaction. Prior to the buy-in transaction,
the Plan surplus was not recognised on the grounds that Airwair
International Limited was unlikely to derive any future economic
benefitsfromthesurplus.However,followingthetransaction,theasset
ceiling has been removed with the surplus recognised in full, on
the basis that any surplus now represents a true economic surplus.
The net surplus of £3.0m (FY25: £nil) has been recognised on the
Balance Sheet. Further details on the pension buy-in are given in
notes 4 and 30 of the Consolidated Financial Statements.
NET DEBT
Reduced year-on-year by £36.0m to £213.5m as summarised below;
£m
29 March
2026
30 March
2025
Bank loans (excluding unamortised bank fees) (250.0) (250.0)
Cash 180.3 155.9
Net bank loans (69.7) (94.1)
Lease liabilities (143.8) (155.4)
Net Debt
1
(213.5) (249.5)
LEASE LIABILITIES
New lease commitments and remeasurements during the period
were £38.0m, largely relating to £22.3m of remeasurements.
This was offset by £55.6m of lease repayments. Average lease
length is low, at 2.4 years to break (FY25: 2.6 years), with the
average lease length we expect to utilise being 2.9 years (FY25:
3.2 years) reflected on the Balance Sheet.
£m
29 March
2026
30 March
2025
Average lease
length to break
(years)
Stores 106.0 111.4 2.6
Offices,warehousesandother 37.8 44.0 1.3
Lease liabilities 143.8 155.4 2.4
RETURNS TO SHAREHOLDERS
Our capital allocation framework guides our view of returns to
shareholders and usage of excess cash. We have a target leverage of
less than 1.5x Net Debt/EBITDA through the year. There are four uses
ofcapitalforourbusiness.Thefirstisinvestmentintothebusiness,
for instance into the brand or through capex into stores, systems and
other investment projects. We also maintain a progressive dividend
policy of 25% to 35% earnings payout. The Board will also consider
strategic investments and additional capital returns to shareholders
in a situation when excess cash is available and we are below our
target leverage.
DIVIDENDS
TheBoarddeclaresafinaldividendof1.70p,takingthetotaldividend
for FY26, including the interim dividend of 0.85p, to 2.55p, in line with
the FY25 dividend payment. This will be paid to shareholders on the
register as at 28 August with payment on 7 October.
£m FY26 FY25
Dividends paid during the period:
Priorperiodfinaldividendpaid 16.4 9.5
Prior period interim dividend paid 8.2 –
Total dividends paid during the period 24.6 9.5
Profit for the period 23.8 4.5
Dividend in respect of the period:
Interim dividend: 0.85p (FY25: 0.85p) 8.2 8.2
Final dividend: 1.70p (FY25: 1.70p) 16.3 16.4
Total dividend in respect of the period 24.5 24.6
Payout ratio % 103% 547%
MOVING TO MARKET-BASED DISCLOSURE
In FY27 we intend to move to market-based reporting, and no
longer report regional revenues, in line with the new operating model
forthebusiness.Wewillpublishhistoricalfinancialdataonthe
newreportingstructureaheadofthefirsthalfresultsinNovember.
GILES WILSON
CHIEF FINANCIAL OFFICER
19 MAY 2026
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
STRATEGIC REPORT
39
DR. MARTENS PLC ANNUAL REPORT 2026

FY26FY25FY24FY23
£764.9m
£787.6m
£877.1m
£1,000.3m
FY26FY25FY24FY23
£57.0m
£37.0m
£122.2m
£176.2m
FY26FY25FY24FY23
7.5%
4.7%
13.9%
17.6%
FY26FY25FY24FY23
£55.0m
£34.1m
£97.2m
£174.0m
FY26FY25FY24FY23
2.5p
0.5p
7.0p
12.9p
FY26FY25FY24FY23
£141.1m
£189.8m
£158.3m
110%
162%
80%
£48.4m
20%
What are we measuring and why?
Revenue arises from the sale of products to
consumers and is stated excluding value added tax
and other sales-related taxes. Revenue growth is
crucial for sustainable long-term growth and is driven
through increasing the number of pairs sold through
all channels and attracting and retaining consumers.
Performance
Revenue decreased by 2.9% (1.4% CC) to £764.9m
(£776.3m CC) in FY26, driven by a focus on Full
Price revenue and reduced clearance activities
across our channels.
Key associated risks
1
3
4
5
9
Key associated risks
Key associated risks
1
5
7
9
Key associated risks
Key associated risks
1
5
7
9
Key associated risks
1
5
7
9
Links to strategy
Links to strategy
Links to strategy
Links to strategy
Links to strategy
Links to strategy
Financial
Measuring our
performance
Revenue EBIT
1
EBIT margin
1
KEY PERFORMANCE INDICATORS
Adjusted PBT
1
Basic EPS
1,2
Operating cash flow
1
What are we measuring and why?
EBIT is the Group’s key profit measure to show
performance from operations and demonstrates
our ability to deliver a return on our revenue.
Performance
EBIT increased by 54.1% driven by stronger
margins year on year with COGS and opex being
tightly managed and benefiting from the cost-saving
activities in FY25.
What are we measuring and why?
EBIT margin expresses EBIT as a percentage of
revenue. Our EBIT margin helps assess operational
performance and efficiencies.
Performance
The EBIT margin improvement was the result of the
strong control over both COGS and operating costs,
including the benefit of the Full Price performance.
Adjusted EBIT margin improved from 7.7% to 10.4%.
What are we measuring and why?
AdjustedPBTshowstheGroup’sprofitperformance
before exceptional costs, investment in transformation,
impairment of non-financial assets, currency gains/
(losses) and after financing costs. PBT includes
depreciation, amortisation and net interest costs and
therefore provides another view of our profitability.
Performance
Adjusted PBT increased by 61.3% to £55.0m
(£54.2m CC) due to the increase in EBIT, with
depreciation and amortisation relatively flat
year-on-year.
What are we measuring and why?
EPS is profit after tax per share in issue and
indicates how much profit a company generates for
each share. EPS represents the earnings achieved
for each share and over time growth of this metric
should result in increased shareholder value.
Performance
Basic EPS was four times higher than FY25 due
to the higher profits achieved in the year.
What are we measuring and why?
Operating cash flow shows EBITDA less change in
net working capital, share-based payment expense
and capital expenditure. The level of operating cash
flow generated by the business is important in
assessing the underlying quality of performance and
the sustainability of growth.
Performance
Operating cash flow as a percentage of EBITDA was
110%, a 52%pts decrease compared to FY25 driven
by cash inflow on inventory in FY25, and to a lesser
extent in FY26 as we returned to normalised
inventory levels
1
2
3
4
5
9 1
3
4
5
7
9
1. AlternativePerformanceMeasure(APM)asdefinedintheGlossaryonpages227to229.
2. Refer to Finance review and note 10 of the Consolidated Financial Statements for further information on EPS and diluted EPS.
40
DR. MARTENS PLC ANNUAL REPORT 2026

FY26FY25FY24FY23
10.2m
10.5m
11.5m
13.8m
FY26FY25FY24FY23
63%
65%
61%
52%
FY26FY25FY24FY23
32%
34%
32%
28%
FY26FY25FY24FY23
240
239239
204
The Group monitors several key metrics to track the financial and
non-financial performance of its business. APMs
1
are used as we
believe they provide additional useful information on underlying
trends. The APMs are not defined by IFRS and therefore may
not be directly comparable with other companies’ APMs.
Linkage to remuneration
KEY METRICS WITHIN INCENTIVE PLANS
For FY26, the metrics within both our Global
Bonus Scheme (GBS) and our Long Term
Incentive Plan (LTIP) align with our strategic
objectives. 70% of the GBS is assessed on
stretching adjusted PBT targets and the LTIP
is based equally on cumulative EPS over
the three-year performance period, relative
total shareholder return and operating cash
flow conversion. Both PBT and EPS are
comprehensive profitability measures which
closely align with shareholder value creation.
KEY DRIVERS OF PERFORMANCE
Of the other key financial drivers, revenue
growth, EBIT and EBIT margin all help
to drive profit and long-term sustainable
business growth. While these are not directly
identified as metrics within the GBS and
PSP, they feed into the metrics of PBT and
EPS used in our incentive arrangements.
1
Brand and
product
2
Social, environmental
and climate
3
People and culture
4
Transformation
and change
5
Supply chain
6
Information and
cyber security
7
Financial
8
Legal and
compliance
9
Macroeconomic
uncertainty
10
Business resilience
Key associated risks:
Consumer
Product
Markets
Organisation
Links to strategy
Non-financial
Pairs Direct-to-consumer
Ecommerce mix Directly-operated stores
What are we measuring and why?
The number of boots, shoes and sandals sold during
the period, through all channels.
Performance
During FY26, we sold 10.2m pairs, a decline of 2.5%
compared to FY25 as we focused on the quality of
revenue resulting in constant currency revenue
declining by less than pairs.
What are we measuring and why?
DTC mix shows the combined ecommerce and
retail revenues as a percentage of total revenue.
Performance
FY26 DTC mix was 63%, down 2%pts compared
to FY25, driven by higher wholesale revenues and
a decline in DTC due to reduced clearance activity.
What are we measuring and why?
Ecommerce mix shows the total ecommerce
revenue as a percentage of total revenue. We aim
to grow ecommerce revenue in the medium term
and this metric therefore demonstrates our progress
against this target.
Performance
Ecommerce mix decreased by 2%pts to 32%
which was impacted by the planned reduction
of clearance activity.
What are we measuring and why?
Directly-operated stores shows the total number
of retail stores the Group operates globally.
Increasing our store estate drives retail and
ecommerce revenue growth.
Performance
During FY26 we opened 19 stores and closed
18 stores. Store openings and closings were
spread across the three regions with closures
due to both relocations and closing some
underperforming stores.
Links to strategy
Links to strategy
Links to strategy
Links to strategyKey associated risks
Key associated risks
1
3
4
5
9
10
1
2
3
4
5
9
10
Key associated risks Key associated risks
1
2
5
7
9
10 1
3
4
5
9
10
STRATEGIC REPORT
41
DR. MARTENS PLC ANNUAL REPORT 2026

A separate section explaining how the Board
engages with each of these stakeholder
groups, and how their interests influence
Board decision-making, is set out in the
Governance Report on pages 104 to 107.
The Board’s formal statement under section
172 of the Companies Act 2006 (s.172)
is set out opposite. The stakeholder
engagement disclosures that follow in the
Strategic Report, alongside the Governance
Report disclosures, explain how regard was
had to stakeholder interests during the year.
The principles of s.172 are far-reaching
andreflectedacrosstheactivitiesofthe
wider business. The table below shows
where further information on how each
of the s.172 provisions is applied at
Dr. Martens can be found throughout
this Annual Report.
S.172 Provision Location of more information
The likely consequences of any decision
in the long term
Chair’s Statement (pages 08 and 09)
CEO review (pages 12 to 17)
Our business model (pages 18 and 19)
Our strategy (pages 20 and 21)
Key performance indicators (KPIs)
(pages 40 and 41)
Effective risk management
(pages 48 to 50)
Board activities (pages 100 and 101)
Viability assessment and going concern
(pages 56 and 57)
The interests of the Company’s employees Stakeholder engagement:
Our people (pages 46 and 47)
Sustainability: Governance (pages 74 and 75)
Nomination Committee Report (pages 112
to 119)
Whistleblowing (page 146)
Remuneration Committee Report
(pages 120 to 122)
Governance Report: Our people (page 106)
The need to foster business relationships
with suppliers, customers and others
Our business model (pages 18 and 19)
Our strategy (pages 20 and 21)
Strategy in action (pages 22 to 31)
Sustainability (pages 58 to 76)
Anti-bribery and corruption (page 87)
Governance Report: Our suppliers page 106)
The impact of the Company’s operations
on the community and the environment
Stakeholder engagement: Environment
&communities(page46)
Sustainability (pages 58 to 76)
Climate-related financial disclosures
(pages 77 to 86)
Governance Report: Our environment
&communities(page106)
The desirability of the Company
maintaining a reputation for high
standards of business conduct
Effective risk management (pages 48 to 50)
Division of responsibilities (pages 102
and 103)
Audit and Risk Committee Report
(pages 136 to 146)
Directors’ Report (pages 147 to 151)
The need to act fairly as between
members of the Company
Stakeholder engagement: Owners (page 44)
Relationship with largest shareholder
(page 150)
Annual General Meeting (page 150)
Governance Report: Owners (page 105)
STAKEHOLDER ENGAGEMENT AND SECTION 172 STATEMENT
Meeting the needs
In this section we describe our key stakeholder
groups, why engagement with them matters to
the business and how the Company engages
with them in practice, and summarise the
outcomes of that engagement during FY26.
of our stakeholders
42
DR. MARTENS PLC ANNUAL REPORT 2026

A key responsibility of all directors of UK companies under
the Companies Act 2006 (the Act) is their duty to promote the
success of the company. Specifically, the Act requires that each
of the Directors of Dr. Martens plc must act in a way that they
consider, in good faith, is most likely to promote the success
of the Company for the benefit of its members as a whole, and
in doing so have regard (among other matters) to:
Maintaining a long-term mindset
p.104 to 107
‘the likely consequences of any decision in the long term’
and ‘the desirability of the Company maintaining a reputation
for high standards of business conduct’
Our people p.46 and 47
‘the interests of the Company’s employees’
Consumers, partners and suppliers p.44 and 45
‘the need to foster the Company’s business relationships
with suppliers, customers and others’
Environment and communities p.46
‘the impact of the Company’s operations on the community
and the environment’
Owners p.44
‘the need to act fairly as between members of the Company’
The Board recognises that maintaining strong relationships and
healthy dialogue with the Company’s stakeholders remains critical
to our objective of delivering sustainable growth over the longer
term. The needs of our stakeholders are closely considered by
the Board when discussing matters of strategic significance.
The Board also pays due regard to the potential impact of
proposals tabled for its approval on our stakeholders and
has sought to establish a wider business culture that keeps
stakeholder interests at the heart of decision-making below
Board level.
The Board therefore confirms that, throughout the period under
review, it acted, and continues to act, to promote the long-term
success of the Company for the benefit of shareholders, while
having due regard to the matters set out in Section 172(1)(a) to
(f) of the Act.
While the Board will always favour outcomes that benefit all
stakeholder groups to the greatest extent possible, it is mindful
that achieving this is not always possible. Stakeholder priorities
are wide-ranging and do, at times, compete and conflict. The
Board therefore seeks to take decisions that it believes are most
likely to contribute to the delivery of its strategic priorities, thereby
serving the interests of all stakeholders over the longer term. How
stakeholders were considered in certain key decisions taken by
the Board during the year can be found in the ‘Our stakeholders’
section of the Governance Report on pages 104 to 107.
The general principles set out in Section 172 are also intrinsic
to how the Company operates below Board level and are firmly
embedded within our culture. The interests of our stakeholders
and the ways in which the actions we take as a business impact
their interests are considered as part of decision-making
processes across the Company. Some examples of these are
provided on the following pages and more information can be
found in our Strategic, Sustainability and Governance Reports,
located from pages 01, 58 and 88 respectively.
SECTION 172 STATEMENT
STRATEGIC REPORT
43
DR. MARTENS PLC ANNUAL REPORT 2026

STAKEHOLDER ENGAGEMENT AND SECTION 172 STATEMENT CONTINUED
Why we engage
- Our shareholders are the owners of the Company. Ongoing
engagement supports transparency, accountability and
informed dialogue, and is an important part of the Company’s
approach to meeting its responsibilities under s.172
- Understanding investors’ priorities and maintaining clear, open
dialogue is an important part of operating as a listed company
- Engagement with shareholders also supports the Company’s
approach to acting fairly as between members, including through
consistent communication and equal access to information
How the Company engages
- The Investor Relations function leads regular and transparent
engagement with shareholders, including meetings, investor
roadshows, one-on-one sessions with our largest institutional
investors, group discussions and engagement with
prospective investors
- Leadership, along with Non-Executive Directors where
appropriate, regularly engage with our institutional shareholders
following results and at other key points during the year
- The Director of Investor Relations and Corporate
Communications is responsible for investor engagement and
ensuring that the Board is kept informed of investor views.
These are obtained through direct engagement and via
corporate brokers following results roadshows, meetings
and conferences
- The Company provides regular market updates, including
half-year and full-year financial results and scheduled trading
updates, including on the AGM date and for the key Q3
trading period
- Other corporate channels, including RNS Reach and the
Company’s LinkedIn site, are used to share non-financial,
non-regulatory updates and news stories, supporting wider
and more consistent access to information for shareholders
Why we engage
- Moving from a channel-first to consumer-first mindset is one
of the major shifts of our new strategy
- Understanding consumers’ evolving needs and expectations
helps ensure our products, channels and brand remain relevant